Luca Richeldi

15PUBLICATIONS
54CO-AUTHORS
Molecular targetsGene and molecular therapyPredictive and prognostic markersImmunogenetics (incl. genetic immunology)Intensive care
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|May 05, 2026
Pamufetinib (TAS-115) for chronic fibrosing interstitial lung diseases with a progressive phenotype: a double-blind, multicenter, phase 2b clinical trial.

|Mar 10, 2026
Bexotegrast for treatment of idiopathic pulmonary fibrosis (BEACON-IPF): study protocol for a multinational, phase 2b/3, double-blind, randomised, multicentre, controlled trial.

Wim A Wuyts, Lisa Lancaster, Toby M Maher

|Mar 22, 2025
Trajectories of forced vital capacity in patients with systemic sclerosis-associated interstitial lung disease.

Oliver Distler, Madelon C Vonk, Arata Azuma

|Mar 05, 2025
The interstitial lung disease patient pathway: from referral to diagnosis.

Graham Lough, Rayid Abdulqawi, Gina Amanda

|Dec 23, 2024
Real-World Safety, Tolerability and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Final Report of Post-marketing Surveillance in Japan.

Yoshikazu Inoue, Takashi Ogura, Arata Azuma

|Sep 29, 2023
Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline.

Ganesh Raghu, Sydney B Montesi, Richard M Silver

Pageof 3

Frequent Collaborators

4 joint publications

Yoshikazu Inoue

3 joint publications

Vincent Cottin

3 joint publications

Martin Kolb

3 joint publications

Claudia Valenzuela